Exagen Inc.
Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $3.76
- 52-Week Range
- $2.59 – $9.22
- Market Cap
- $99.50M
- P/E (TTM)
- —
- EPS (TTM)
- -0.76
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 7.20
- PEG Ratio
- —
- Return on Equity
- -113.88%
- Return on Assets
- -14.74%
- Gross Margin
- 58.74%
- Operating Margin
- -19.27%
- Profit Margin
- -25.14%
- Current Ratio
- 3.46
- Debt/Equity
- 2.09
- Total Debt
- $28.76M
- Free Cash Flow
- $-5.71M
- Revenue Growth
- 6.80%
- Earnings Growth
- —
- Enterprise Value
- $100.17M
Market Snapshot
About
Exagen is a commercial-stage diagnostics company focused on transforming the care continuum for patients with autoimmune diseases. The company has developed and commercialized a portfolio of innovative testing products that enable differential diagnosis and monitor disease activity in rheumatic and autoimmune diseases. Exagen specializes in cell-bound complement activation products and other biomarker-based tests.